翔宇医疗(688626) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥168,772,576.52, a decrease of 18.51% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2024 was ¥16,778,072.88, down 76.55% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥10,998,576.80, a decline of 84.27% compared to the previous year[3]. - The basic earnings per share for Q3 2024 was ¥0.11, a decrease of 76.09% compared to the same period last year[3]. - Net profit for the third quarter of 2024 was CNY 73.38 million, a decline of 59.3% compared to CNY 180.20 million in the same quarter of 2023[21]. - The company reported a net profit attributable to shareholders of CNY 73.41 million, a decrease of 59.0% compared to CNY 179.16 million in the previous year[22]. Research and Development - R&D investment totaled ¥38,453,979.63 in Q3 2024, representing an increase of 50.96% year-on-year, accounting for 22.78% of operating revenue[4]. - Research and development expenses rose to CNY 104.12 million, an increase of 42.5% from CNY 72.93 million in the previous year[21]. - During the reporting period, the company obtained 12 new medical device registration certificates, bringing the total to 336[13]. - The company added 134 new patents, including 30 invention patents, for a cumulative total of 1,817 patents[13]. - The company successfully included 24 models of rehabilitation equipment in the tenth batch of excellent domestic medical device product catalog[13]. Assets and Liabilities - Total assets at the end of Q3 2024 reached ¥2,802,730,356.30, an increase of 8.13% from the end of the previous year[4]. - The total equity attributable to shareholders at the end of Q3 2024 was ¥2,025,625,177.97, a decrease of 3.12% from the previous year[4]. - The company's total equity decreased to CNY 2.04 billion, down 3.1% from CNY 2.11 billion in the previous year[19]. - Total liabilities increased to CNY 760.83 million, up 57.0% from CNY 484.69 million year-on-year[19]. - The total amount of non-current liabilities was CNY 136.86 million, an increase of 21.5% from CNY 112.55 million year-on-year[19]. Cash Flow - The net cash flow from operating activities for the year-to-date period decreased by 45.06% due to reduced government subsidies received and increased cash expenses[6]. - The total cash inflow from operating activities for the first three quarters of 2024 was CNY 637,256,246.44, a decrease of 1.44% compared to CNY 647,724,318.67 in the same period of 2023[23]. - The net cash flow from operating activities decreased to CNY 92,978,705.37, down 45.00% from CNY 169,238,341.53 in the previous year[23]. - Cash outflow from operating activities increased to CNY 544,277,541.07, compared to CNY 478,485,977.14 in the same period last year, reflecting a rise of 13.76%[23]. - The cash inflow from investment activities was CNY 324,262,827.10, significantly lower than CNY 1,516,055,387.16 in the previous year, indicating a decrease of 78.66%[25]. - The net cash flow from investment activities was -CNY 186,978,378.01, compared to -CNY 244,969,918.15 in the same period last year[25]. - Cash inflow from financing activities totaled CNY 492,000,000.00, an increase from CNY 278,730,141.17 in the previous year, representing a growth of 76.36%[25]. - The net cash flow from financing activities was CNY 151,233,716.66, slightly up from CNY 149,349,919.32 in the same period last year[25]. - The ending balance of cash and cash equivalents was CNY 709,126,445.75, down from CNY 790,452,828.66 at the end of the previous year[25]. - The company received CNY 324,000,000.00 in loans during the financing activities, a significant increase from CNY 75,000,000.00 in the previous year[25]. Inventory and Fixed Assets - The company’s fixed assets rose to CNY 509,307,243.89 from CNY 396,899,151.13 year-over-year[17]. - The company’s inventory stood at CNY 240,905,036.20, slightly down from CNY 241,366,072.32[17]. - The company’s non-current assets totaled CNY 1,670,821,158.40, an increase from CNY 1,397,773,485.02 in the previous year[17].